Skip to Content


Treatment for Pain

QRxPharma Refiles MoxDuo New Drug Application with the FDA

November 26, 2013 -- Sydney, Australia and Bedminster, New Jersey – QRxPharma Limited announced today that the Company resubmitted its MoxDuo New Drug Application (NDA). At a meeting in early October, the United States Food and Drug Administration (FDA) provided QRxPharma with guidance on its requirements for the NDA refiling as well as data validation documentation. “We are confident that our refiled NDA will confirm the validity of the data defining the product’s respiratory safety advantages and we are hopeful that the FDA will view them favourably in their consideration of the benefits of immediate release MoxDuo as a therapeutic option for the millions of patients who suffer from acute pain,” said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. “We were encouraged by our candid dialogue with the FDA throughout this process, and will continue to liaise closely with the Agency to bring MoxDuo to market.”

The FDA previously confirmed that the Company’s Combination Rule Trial, Study 008, satisfied efficacy requirements and that there were no efficacy or safety issues identified in any of the studies submitted in the original NDA.

QRxPharma completed an audit of the more than 30 million data points for oxygen desaturation from Study 022. We believe these data demonstrate a significant respiratory safety advantage for MoxDuo over equi-analgesic doses of morphine or oxycodone. Furthermore, MoxDuo provides a lower starting dose and finer dose titration steps than acute pain opioids presently available, giving greater flexibility to physicians and patients as the need for pain relief is balanced with lower risks of side effects.

We expect the FDA to schedule an Advisory Committee meeting preceding a Prescription Drug User Fee Act (PDUFA) date six months following this submission, projected for late May, 2014.

“We will keep our shareholders informed as we receive feedback from the FDA, and assuming approval, we anticipate product launch with our US commercialisation partner, Actavis, in the second half of CY2014,” added Holaday.

The revised NDA is the basis for recommencing the regulatory approval for MoxDuo for the treatment of moderate to severe pain, a US $2.5 billion segment of the US $8 billion spent annually on prescription opioids in the US.

Source: QRxPharma

Posted: November 2013

Related Articles

MoxDuo (morphine and oxycodone) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.